Woman Files Lawsuit after Suffering Three Gastrointestinal Bleeds, Allegedly While Taking the Blood Thinner, Plavix

Share Article

Parker Waichman LLP has filed a lawsuit on behalf of a Tennessee woman who suffered three gastrointestinal hemorrhages, allegedly due to the use of Plavix (clopidogrel). The anti-platelet drug, which went off patent in May, has been associated with an increased risk of bleeding events. The lawsuit alleges that Sanofi-Aventis and Bristol-Myers Squibb made false claims about the safety of Plavix, placing the Plaintiff and the public at risk.

News Image

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a lawsuit alleging that Plavix caused three episodes of gastrointestinal hemorrhaging in one woman. The suit was filed on July 26th in the Supreme Court of the State of New York, County of New York (Index No. 154922/2012). Bristol-Myers Squibb Company, Sanofi-Aventis U.S., L.L.C., Sanofi US Services Inc., and Sanofi-Synthelabo, Inc. have been named as Defendants.

According to the Complaint, the Plaintiff is a woman from Decatur, Tennessee who began taking Plavix in April 2011. Thereafter, she suffered three gastrointestinal hemorrhages, most recently in September 2011. The lawsuit alleges that Plavix caused the multiple bleeding episodes and holds the Defendants responsible for making misleading statements about the safety of the medication. As a result of these conditions, the suit alleges that the Plaintiff has suffered severe and permanent injuries, physical impairment and disfigurement, physical pain and suffering, mental pain and suffering and loss of enjoyment of life. The lawsuit also states that the Plaintiff has incurred and will continue to incur various sums of money due to past, present and future medical expenses associated with her injuries.

Among other things, the Defendants are accused of unethical business practices with regards to marketing Plavix, which was approved to prevent atherosclerotic events in high risk patients. The suit points out that its approval was based on a single study comparing the medication to Aspirin, known as CAPRIE (Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events). According to the Complaint, the Defendants marketed Plavix in direct defiance to the U.S. Food and Drug Administration (FDA), who stated that Plavix should not replace Aspirin as a first-line therapy for preventing ischemic events.

Allegedly, the Defendants touted Plavix as “super-aspirin” in order to protect their financial interests. According to the lawsuit, Plavix has generated $42.8 billion in sales since its approval in 1997; the drug generated $7.1 billion in 2011 alone. Despite the Defendants’ claims, the lawsuit cites a number of research studies that suggest the Aspirin is equally, if not more, beneficial than Plavix in certain patients. For instance, the Defendants insisted that Plavix is safe when taken in combination with Aspirin. However, a study in the New England Journal of Medicine (NEJM) found that this so-called “dual therapy” was not more effective than Aspirin alone.

Plavix went off patent in May, making way for a number of generic versions. According to Parker Waichman, these generic equivalents carry the same risks as brand-name Plavix.

Parker Waichman LLP continues to offer free legal consultations to victims of alleged Plavix side effects, including:

  •     Cerebral hemorrhage
  •     Thrombotic Thrombocytopenic Purpura (TTP)
  •     Gastrointestinal bleeding
  •     Ulcers
  •     Internal bleeding
  •     Bone marrow damage
  •     Heart attack
  •     Stroke
  •     Death

If you or a loved experienced serious, life-threatening internal bleeding, heart attacks, strokes, or a blood disorder, and you believe Plavix is to blame, please contact their office by visiting the firm's Plavix side effects page at yourlawyer.com. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).

Parker Waichman LLP
Gary Falkowitz, Managing Attorney
(800) LAW-INFO
(800) 529-4636

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Gary Falkowitz
Follow us on
Visit website